EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis

Garifallia Sakellariou, 1 Philip G Conaghan, 2 Weiya Zhang, 3 Johannes W J Bijlsma, 4 Pernille Boyesen, 5 Maria Antonietta D’Agostino, 6, 7 Michael Doherty, 5 Daniela Fodor, 8 Margreet Kloppenburg, 9 Falk Miese, 10 Esperanza Naredo, 11 Mark Pocheret, 12 Annamaria Iagnocco 13

ABSTRACT
The increased information provided by modern imaging has led to its more extensive use. Our aim was to develop evidence-based recommendations for the use of imaging in the clinical management of the most common arthropathy, osteoarthritis (OA). A task force (including rheumatologists, radiologists, methodologists, primary care doctors and patients) from nine countries defined 10 questions on the role of imaging in OA to support a systematic literature review (SLR). Joints of interest were the knee, hip, hand and foot; imaging modalities included conventional radiography (CR), MRI, ultrasonography, CT and nuclear medicine. PubMed and EMBASE were searched. The evidence was presented to the task force who subsequently developed the recommendations. The strength of agreement for each recommendation was assessed. 17 011 references were identified from which 390 studies were included in the SLR. Seven recommendations were produced, covering the lack of need for diagnostic imaging in patients with typical symptoms; the role of imaging in differential diagnosis; the lack of benefit in monitoring when no therapeutic modification is related, though consideration is required when unexpected clinical deterioration occurs; CR as the first-choice imaging modality; consideration of how to correctly acquire images and the role of imaging in guiding local injections. Recommendations for future research were also developed based on gaps in evidence, such as the use of imaging in identifying therapeutic targets, and demonstrating the added value of imaging. These evidence-based recommendations and related research agenda provide the basis for sensible use of imaging in routine clinical assessment of people with OA.

INTRODUCTION
Osteoarthritis (OA) is a major cause of pain and disability worldwide. Although conventional radiography (CR) is the most commonly used technique to evaluate structural features of OA, significant advances have been made in the field of imaging over the last decade, allowing a more accurate evaluation of both bone and soft-tissue abnormalities. While newer modalities such as MRI and ultrasound have increased the understanding of the multiple pathologies contributing to the OA phenotype, it is not clear how they should be used in routine care. The role of imaging in clinical practice for OA diagnosis, management and follow-up has not been clearly defined. Despite this limitation, the increased availability of modern imaging has expanded its use, with possible excesses leading to increased costs. A European League Against Rheumatism (EULAR) task force was therefore created to develop evidence-based recommendations on the use of imaging in the management of symptomatic, peripheral joint OA, for clinicians who treat OA in their clinical practice.

METHODS
A group selected from a range of expertise (rheumatologists, radiologists, primary care physicians, methodologists and patients) and representing nine countries was included in the task force. During the first meeting, the focus of the recommendations (symptomatic OA affecting the knee, hip, hand or foot) was clarified. Clinically relevant questions on the application of imaging in OA were proposed and nine research questions were selected by consensus to guide a systematic literature review (SLR). Two questions that covered the same area were subsequently combined. The areas of diagnosis, prognosis, follow-up and treatment were covered. The questions were rephrased according to the population, intervention, comparison, outcome (PICO) (see online supplementary file S1 research questions).

An SLR was performed by one of the authors (GS), with checking of all extractions by one of three other authors experienced in SLRs. The search strategies were based on both MeSH terms and free text. The searches were performed separately for each joint (see online supplementary file S2 search strategies). The titles and abstracts of the references that were retrieved were screened by the same author according to predefined inclusion and exclusion criteria, based on the PICO for each question, and potentially relevant articles were evaluated in their full text. Studies in English including adults (≥18) with symptomatic OA of the knee, hip, hand and foot were eligible for inclusion. Imaging modalities included were CR, MRI, ultrasonography (US), CT and nuclear medicine techniques (scintigraphy, positron emission tomography). Randomised controlled trials (RCTs), systematic reviews and meta-analyses, controlled clinical trials, case-control studies, cross-sectional studies and cohort studies were eligible for inclusion. Studies had to examine the role of imaging in
Recommendation

Table 1 summarises the seven recommendations with their corresponding level of evidence and LOA. Each recommendation is presented in detail below.

**Overarching statements**

1. These recommendations pertain only to symptomatic OA.
2. Imaging abnormalities of OA are commonly seen especially with increasing age.

**Table 1** Recommendations, levels of evidence and level of agreement (LOA)

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Level of evidence</th>
<th>LOA, mean (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Imaging is not required to make the diagnosis in patients with typical* presentation of OA.</td>
<td>III–IV</td>
<td>8.7 (7.9 to 9.4)</td>
</tr>
<tr>
<td>2. In atypical presentations, imaging is recommended to help confirm the diagnosis of OA and/or make alternative or additional diagnoses.</td>
<td>IV</td>
<td>9.6 (9.1 to 10)</td>
</tr>
<tr>
<td>3. Routine imaging in OA follow-up is not recommended. However, imaging is recommended if there is unexpected rapid progression of symptoms or change in clinical characteristics to determine if this relates to OA severity or an additional diagnosis.</td>
<td>III–IV</td>
<td>8.8 (7.9 to 9.7)</td>
</tr>
<tr>
<td>4. If imaging is needed, conventional (plain) radiography should be used before other modalities. To make additional diagnoses, soft tissues are best imaged by US or MRI and bone by CT or MRI.</td>
<td>III–IV</td>
<td>8.7 (7.9 to 9.6)</td>
</tr>
<tr>
<td>5. Consideration of radiographic views is important for optimising detection of OA features; in particular for the knee, weightbearing and patellofemoral views are recommended.</td>
<td>III</td>
<td>9.4 (8.7 to 9.9)</td>
</tr>
<tr>
<td>6. According to current evidence, imaging features do not predict non-surgical treatment response and imaging cannot be recommended for this purpose.</td>
<td>II–III</td>
<td>8.7 (7.5 to 9.7)</td>
</tr>
<tr>
<td>7. The accuracy of intra-articular injection depends on the joint and on the skills of the practitioner and imaging may improve accuracy. Imaging is particularly recommended for joints that are difficult to access due to factors including site (eg, hip), degree of deformity and obesity.</td>
<td>III–IV</td>
<td>9.4 (8.9 to 9.9)</td>
</tr>
</tbody>
</table>

**Categories of evidence:** Ia, evidence for meta-analysis of randomised controlled trials; Ib, evidence from at least one randomised controlled trial; Iia, evidence from at least one controlled study without randomisation; Iib, evidence from at least one other type of quasi-experimental study; II, evidence from non-experimental descriptive studies, such as comparative studies, correlation studies and case–control studies; IV, evidence from expert committee reports or opinions or clinical experience of respected authorities, or both LOA: 0–10 numerical rating scale.

*Typical features include usage-related pain, short duration morning stiffness, age >40, symptoms affecting one or a few joints.

OA, osteoarthritis; US, ultrasonography.
3. Joint symptoms are also common and increase with age. Symptoms are not always causally related to imaging abnormalities.

4. Full history and examination is always required before considering the need for investigations, including imaging.

5. Modern imaging modalities provide the capability to detect a wide range of soft tissue, bony and cartilage pathology in OA. However, the increased information provided has not yet had any influence on clinical decision-making with respect to management.

Making a diagnosis of OA
Recommendation 1: Imaging is not required to make the diagnosis in patients with typical presentation of OA.

- Level of evidence: III–IV LOA (95% CI) 8.7 (7.9 to 9.4)
- Although many studies applied imaging for diagnostic purposes, there was a lack of studies in which imaging was applied in addition to clinical findings to evaluate its additional impact on the certainty of diagnosis, which was a predefined criterion for inclusion.

A single study examined the added value of US of hand and feet over clinical findings in a cohort of patients with suspected or confirmed arthritis. When US was added to clinical findings, the diagnostic confidence in differentiating OA from inflammatory arthritis significantly increased. Due to the absence of strong evidence supporting the use of different imaging modalities at different anatomical sites, the systematic use of imaging in the diagnostic process was not recommended in cases with typical clinical presentation. However, based on the joint site and clinical presentation, imaging might be considered when diagnoses other than OA are suspected. This aspect has been taken into account in Recommendation 2.

Recommendation 2: In atypical presentations, imaging is recommended to help confirm the diagnosis of OA and/or make alternative or additional diagnoses.

- Level of evidence: IV LOA (95% CI) 9.6 (9.1 to 10)
- Studies were eligible for inclusion if they investigated the added value of imaging for differential diagnosis over clinical evaluation. Among studies evaluating the application of imaging for differential diagnosis, no study evaluated the impact of the addition of imaging above clinical findings. The possible application in atypical clinical scenarios was however recognised by the experts, which included this point in the recommendation.

Monitoring disease
Recommendation 3: Routine imaging in OA follow-up is not recommended. However, imaging is recommended if there is unexpected rapid progression of symptoms or change in clinical characteristics to determine if this relates to OA severity or an additional diagnosis.

- Level of evidence: III–IV LOA (mean, 95% CI) 8.8 (7.9 to 9.7)
- A specific question addressed the use of imaging for the follow-up. The 117 studies (mostly cohort studies) retrieved covered all joint sites except the foot and all imaging modalities except CT (see online supplementary figure S9). Most of the 83 included studies focused on sensitivity to change. The remaining studies investigated the trajectories of changes of elementary lesions detected by imaging when following OA natural history or described the parallel changes between different abnormalities detected by different imaging modalities. Only a minority of studies examined the correlation between the change in imaging features and symptoms or relevant clinical outcomes (table 2) and only four US studies evaluated the change of imaging after treatment (see online supplementary file S10).

Moreover, there were no studies comparing clinical follow-up with imaging follow-up or strategies adding imaging to clinical management.

The impact of imaging in the management of OA was also specifically addressed by the literature search. Three studies addressed this point. One RCT evaluating the impact of MRI in patients with knee pain assessed in a general practice setting showed that MRI led to an increase in therapeutic confidence but no significant changes in management.

A cross-sectional study in an orthopaedic setting investigating the impact of CR over management decisions in knee OA showed that CR led to the change in the opinion in 166/400 cases. A similar study evaluating the impact of CR in the assignment of priority for surgery in hip OA showed a relative risk (95% CI) of 1.98 (1.23 to 3.19) for an earlier assignment in patients with more severe radiographic scores. No studies evaluated the impact of imaging for the management of hand or foot OA and no studies specifically addressed the issue of non-surgical management.

Recommendation 4: If imaging is needed, conventional (plain) radiography should be used before other modalities. To make additional diagnoses, soft tissues are best imaged by US or MRI and bone by CT or MRI.

- Level of evidence: III–IV LOA (95% CI) 8.7 (7.9 to 9.6)
- The performance of imaging in the detection of OA elementary lesions was addressed by the literature search. CR was the imaging modality that was most frequently used for diagnostic, prognostic and follow-up purposes. However, no studies of the cost-effectiveness of each imaging modality or their sequence were found. In the absence of appropriate literature, the experts decided to emphasise the role of the most easily available and less costly imaging modality, proposing as second-level investigations techniques that, due to their characteristics, are more suitable for the detailed assessment of soft tissues (MRI and US) or bone (CT).

Recommendation 5: Consideration of radiographic views is important for optimising detection of OA features; in particular for the knee, weightbearing and patellofemoral views are recommended.

- Level of evidence: III LOA (95% CI) 9.4 (8.7 to 9.9)
- This topic was addressed by an additional research question, evaluating the optimal combination of radiographic views in OA. Twenty-seven studies comparing different views for knee OA were included. In this context, all studies involving the tibiofemoral compartment considered weightbearing views, both in extension and various degrees of flexion.


Typical features include usage-related pain, short duration morning stiffness, age >40, symptoms affecting one or a few joints.

3-8, 10, 17, 25, 118, 123, 137–144

#19

61

139

148

149

The flexed views demonstrated superiority in detecting joint...
space narrowing, a greater sensitivity to change and reproducibility compared with extended views.143 144 149 With surgery as reference standard, the skyline view had greater sensitivity and specificity to detect cartilage damage at the patellofemoral joint.150

There were five studies assessing the hip. Three studies compared weightbearing and supine anteroposterior (AP) views of the pelvis, one of them showing greater average and maximal joint space width detected by the weightbearing view; the

Table 2  Studies correlating changes in imaging findings with symptoms, function or clinical outcome

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Site</th>
<th>Study design</th>
<th>Imaging</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fukui et al., 2010103</td>
<td>68</td>
<td>Knee</td>
<td>Cohort</td>
<td>CR</td>
<td>Correlation between radiographic progression and pain function scores</td>
</tr>
<tr>
<td>Eckstein et al., 2014104</td>
<td>189</td>
<td>Knee</td>
<td>Case–control</td>
<td>MRI</td>
<td>OR (95% CI) for cartilage loss in patients undergoing TKA vs controls: 1.36 (1.08 to 1.70)</td>
</tr>
<tr>
<td>Kornaat et al., 2007105</td>
<td>182</td>
<td>Knee</td>
<td>Cohort</td>
<td>MRI</td>
<td>Change in BMLs/change in WOMAC pain and function</td>
</tr>
<tr>
<td>Phan et al., 2006106</td>
<td>34</td>
<td>Knee</td>
<td>Cohort</td>
<td>MRI</td>
<td>No significant differences in WOMAC pain and function depending on the changes of BMLs</td>
</tr>
<tr>
<td>Zhang et al., 2011107</td>
<td>651</td>
<td>Knee</td>
<td>Cohort</td>
<td>MRI</td>
<td>Changes in BMLs and synovitis severity (worsening or improving) significantly related to the risk of frequent knee pain (p=0.006 for worsening BMLs and p=0.045 for improving BMLs) no significant correlation with changes in effusion severity</td>
</tr>
<tr>
<td>Haugen et al., 2013106</td>
<td>190</td>
<td>Hand</td>
<td>Cohort</td>
<td>CR</td>
<td>Joint space narrowing, a greater sensitivity and specificity to detect cartilage damage at the patellofemoral joint.150</td>
</tr>
</tbody>
</table>

BMLs, bone marrow lesions; CR, conventional radiography; KLG, Kellgren and Lawrence grade; N, number of participants; TKA, total knee arthroplasty; WOMAC, Western Ontario MacMaster Universities Arthritis Index.

Table 3  Summary of studies evaluating imaging in the prediction of response to treatment: systemic treatment

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Site</th>
<th>Study design</th>
<th>Imaging</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gudbergsen et al., 2012156</td>
<td>192</td>
<td>Knee</td>
<td>RCT CR MRI</td>
<td>mJSW, alignment and MRI scores/pain reduction in response to very-low-energy diet or low-energy diet</td>
<td>Among all radiographic and MRI parameters, only effusion score was significantly related to a reduction in pain</td>
</tr>
<tr>
<td>Gudbergsen et al., 2011157</td>
<td>30</td>
<td>Knee</td>
<td>RCT CR MRI</td>
<td>KLG and MRI score/change in WOMAC pain</td>
<td>No significant association between KLG and MRI score and WOMAC</td>
</tr>
<tr>
<td>Hellio le Graverand et al., 201314</td>
<td>1452</td>
<td>Knee</td>
<td>RCT CR</td>
<td>KLG/radiographic progression in patients treated with cindunistat or placebo at 96 weeks</td>
<td>No significant difference between KLG2 and KLG3 in terms of progression of joint space narrowing in both cindunisat and placebo group</td>
</tr>
<tr>
<td>Case et al., 2003158</td>
<td>82</td>
<td>Knee</td>
<td>RCT CR</td>
<td>KLG and medial JSN/WOMAC response to diclofenac vs paracetamol at 12 weeks</td>
<td>Patients with KLG 1–2 and not 3–4 and JSN grade 0–1 compared with 2 had a better response to diclofenac vs both placebo and paracetamol</td>
</tr>
<tr>
<td>Sawitzke et al., 2008159</td>
<td>375</td>
<td>Knee</td>
<td>RCT CR</td>
<td>KLG/radiographic progression during treatment with glucosamine, chondroitin sulfate and celecoxib at 24 months</td>
<td>OR for radiographic progression compared with the placebo group was &lt;1 in patients with KLG 2 knees in all treatment groups, whereas it was &gt;1 in patients with KLG 3 knees in all treatment groups</td>
</tr>
<tr>
<td>Mazza et al., 2010160</td>
<td>379</td>
<td>Knee</td>
<td>RCT CR</td>
<td>Alignment/radiographic progression in doxycycline vs placebo at 30 months</td>
<td>Varus knees exhibited a greater loss of JSW than non-varus knees in patients receiving doxycycline</td>
</tr>
<tr>
<td>Knoop et al., 2014164</td>
<td>91</td>
<td>Knee</td>
<td>Cohort</td>
<td>MRI</td>
<td>MRI/change in WOMAC function in response to exercise programme at 12 weeks</td>
</tr>
<tr>
<td>Wenham et al., 2012168</td>
<td>65</td>
<td>Hand</td>
<td>RCT MRI</td>
<td>MRI</td>
<td>MRI/response to prednisolone 5 mg at 12 weeks</td>
</tr>
<tr>
<td>Lequesne et al., 2002169</td>
<td>163</td>
<td>Hip</td>
<td>RCT CR</td>
<td>JSW/radiographic progression in patients treated with avocado soybean at 2 years</td>
<td>In patients with smaller JSW treated with avocado soybean, the reduction of JSW was half than in the placebo group; no differences in patients with more JSW</td>
</tr>
<tr>
<td>Rozendaal et al., 2009171</td>
<td>222</td>
<td>Hip</td>
<td>RCT CR</td>
<td>KLG/WOMAC pain and function, JSN in patients taking glucosamine at 2 years</td>
<td>Significantly better WOMAC function response in patients with KLG 1 compared with KLG 2; no differences in WOMAC pain and JSN</td>
</tr>
<tr>
<td>Hoeksm et al., 2005172</td>
<td>103</td>
<td>Hip</td>
<td>RCT CR</td>
<td>KLG/Harris Hip score and range of motion in response to manual therapy vs exercise</td>
<td>Better response in terms of range of motion in lower compared with higher radiographic grades</td>
</tr>
</tbody>
</table>

CR, conventional radiography; JSN, joint space narrowing; JSW, joint space width; KLG, Kellgren and Lawrence grade; mJSW, minimal joint space width; N, number of participants; OARSI, Osteoarthritis Research Society International; RCT, randomised controlled trial; WOMAC, Western Ontario MacMaster Universities Arthritis Index.
remaining showing inconsistent results. Two studies comparing pelvis, hip and oblique views projections in terms of reliability and sensitivity to change demonstrated similar reliability for views dedicated to the hip and views including all the pelvis, with comparable sensitivity to change. No studies assessing the hand and the foot were found.

Role in prognosis

Recommendation 6: According to current evidence, imaging features do not predict non-surgical treatment response and imaging cannot be recommended for this purpose. Level of evidence: II–III. LOA (95% CI) 8.7 (7.5 to 9.7)

Two specific research questions addressed the role of imaging in prognosis, referring to both the prediction of the natural history and to the prediction of non-surgical treatment outcomes. A number of studies addressed the issue of the prognostic value of imaging as predictor of the natural history of OA (see online supplementary figure S12), while only a minority of studies, evaluating all joint sites, investigated the role in predicting treatment response. Due to the heterogeneity in populations, interventions, treatment and study design, a meta-analysis was not possible. In addition, progression of some imaging pathologies may have limited clinical significance. Tables 3 and 4 summarise the results of the 28 primary studies in which imaging was applied to predict treatment response. Moreover, an existing SLR was available, without a quantitative synthesis. The results on the prediction of response were mostly inconsistent across studies; for this reason the use of imaging for this purpose was not recommended.

Treatment (imaging-guided procedures)

Recommendation 7: The accuracy of intra-articular injection depends on the joint and on the skills of the practitioner and imaging may improve accuracy. Imaging is particularly recommended for joints that are difficult to access due to factors including site (e.g. hip), degree of deformity and obesity. Level of evidence: III–IV. LOA (95% CI) 9.4 (8.9 to 9.9)

A search addressing the impact of imaging to guide intra-articular injections was run specifically for OA in the beginning. Including only studies comparing imaging-guided to blind procedures, four primary studies were found for the knee and one for the hand, and a qualitative SLR for the knee (table 5). The added value of US was addressed by four studies, while fluoroscopic guidance was tested in a single study.

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Site</th>
<th>Imaging</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrett et al., 1990</td>
<td>248</td>
<td>Knee</td>
<td>CR</td>
<td>Radiographic severity/response to intra-articular HA at 6 months</td>
</tr>
<tr>
<td>Gaffney, 1995</td>
<td>84</td>
<td>Knee</td>
<td>RCT</td>
<td>OA severity 0–3/response to intra-articular triamcinolone vs placebo at 3 weeks</td>
</tr>
<tr>
<td>Toh et al., 2002</td>
<td>60</td>
<td>Knee</td>
<td>Cohort</td>
<td>Alignment, sclerosis, cysts, osteophytes, JSN/WOMAC response to intra-articular HA at 12 weeks</td>
</tr>
<tr>
<td>Pendleton et al., 2008</td>
<td>86</td>
<td>Knee</td>
<td>Cohort</td>
<td>US/WOMAC response to intra-articular methylprednisolone</td>
</tr>
<tr>
<td>Chao et al., 2010</td>
<td>67</td>
<td>Knee</td>
<td>RCT</td>
<td>US inflammation/WOMAC response to triamcinolone at 12 weeks</td>
</tr>
<tr>
<td>Anandacoomarasamy et al., 2008</td>
<td>32</td>
<td>Knee</td>
<td>Cohort</td>
<td>Cartilage volume/response to intra-articular HA at 6 months</td>
</tr>
<tr>
<td>Drakonaki, 2011</td>
<td>51</td>
<td>Foot</td>
<td>Cohort</td>
<td>Positive therapeutic response (intra-articular, methylprednisolone) at 12 months</td>
</tr>
<tr>
<td>Han et al., 2011</td>
<td>40</td>
<td>Foot</td>
<td>Cohort</td>
<td>Response to intra-articular HA (VAS pain) at 12 months</td>
</tr>
<tr>
<td>Sun et al., 2011</td>
<td>46</td>
<td>Foot</td>
<td>Cohort</td>
<td>KLG 2 and 3/AOS, AOFAS scores in response to intra-articular HA</td>
</tr>
<tr>
<td>Mallinson et al., 2013</td>
<td>31</td>
<td>Hand</td>
<td>Cohort</td>
<td>CR and US/response to intra-articular triamcinolone at 6 weeks</td>
</tr>
<tr>
<td>Atchua et al., 2011</td>
<td>77</td>
<td>Hip</td>
<td>RCT</td>
<td>Synovitis/response to intra-articular methylprednisolone at 6 weeks</td>
</tr>
<tr>
<td>Renneson-Rey et al., 2008</td>
<td>55</td>
<td>Hip</td>
<td>Cohort</td>
<td>Effusion and KLG/OARSI response to HA at 6 months</td>
</tr>
<tr>
<td>Deshmukh et al., 2011</td>
<td>220</td>
<td>Hip</td>
<td>Cohort</td>
<td>KLG/pain relief after methylprednisolone injections at 2 weeks</td>
</tr>
<tr>
<td>Robinson et al., 2007</td>
<td>120</td>
<td>Hip</td>
<td>Cohort</td>
<td>US osteophytes and capsular thickening, KLG/WOMAC response to intra-articular CS at 12 weeks</td>
</tr>
</tbody>
</table>

AOFAS, Australian Orthopedic Foot and Ankle Society; AOS, Ankle Osteoarthritis score; CR, conventional radiography; CS, corticosteroids; HA, hyaluronic acid; JSN, Joint Space Narrowing; KLG, Kellgren and Lawrence grade; N, number of participants; OA, osteoarthritis; OARSI, Osteoarthritis Research Society International; RCT, randomised controlled trial; US, ultrasonography; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
In order to retrieve further information on this topic, an additional search was performed (see online supplementary file S1 for search strategies), including studies comparing blind to guided injections in OA and also in other conditions. This search found eight studies, of which three were already included in the previous results (see online supplementary file S1). Most of the studies were focused on the knee, with some studies on the hand and the foot, while no studies were found for the hip. All the additional studies investigated the impact of US. Accuracy was found to be better in imaging guided compared with blind procedures; however, the results on the clinical outcomes of the injection were less consistent across studies. For these reasons, the systematic use of imaging to drive injections was not recommended, leaving this tool to drive injection in specific situations, identified by the experts. Although the imaging modality is not specified in the recommendation, there is published evidence for the use of US, and imaging allows for real-time evaluation of injection placement.

Future research agenda
The most important topics to drive future research were selected by the Task Force based on the (often considerable) gaps in the evidence and the needs arising from clinical practice (table 6).

DISCUSSION
Although a number of recommendations have been made on how to use imaging in OA clinical trials, these are the first recommendations on the use of imaging in OA in clinical practice. The development of the recommendations started from questions of clinical relevance selected by a task force of experts, with the aim to focus on topics of interest for clinical practice rather than research. The literature review identified a large number of studies, covering most joint sites. However, a possible limitation of this work is that we used a search term of ‘osteoarthritis’ and not ‘pain’, and it is possible we missed studies that imaged painful sites without specifically mentioning OA; this may explain the paucity of foot pain studies included. Although CR was still the most frequently applied technique, a substantial number of studies focused on modern imaging, MRI and US in particular.

However, despite the amount of data available in the literature, only a small part of this information was relevant for clinical practice. For this reason, many areas needing further investigation were identified. In particular, there was a lack of strategic studies investigating the additional value of imaging over clinical findings in making a diagnosis of OA, in the management and the follow-up of the disease, and inconsistent results dealing with the prediction of the outcome of non-pharmacological treatments. The absence of good study information in these areas did not enable the Task Force to recommend systematic imaging in all these areas. A research agenda was therefore generated in order to address these topics in the future research.

In conclusion, seven recommendations covering different areas in the routine management of OA were developed. These are based on both available scientific evidence and expert opinion to provide a valuable and sensible guide for the use of imaging in clinical practice.

Table 5 Studies comparing imaging-guided to blind injections in OA

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Site</th>
<th>Study design</th>
<th>Imaging</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burn Park, 2013</td>
<td>99</td>
<td>Knee</td>
<td>RCT</td>
<td>US</td>
<td>Accuracy of HA injection vs blind injection OR (95% CI) for an accurate injection with US compared with blind: 4.68 (0.94 to 23.30)</td>
</tr>
<tr>
<td>Im et al., 2009</td>
<td>99</td>
<td>Knee</td>
<td>RCT</td>
<td>US</td>
<td>Accuracy of HA injection vs blind injection Accurate injections: 95.5% (US-guided) vs 77.2% (blind); p=0.01</td>
</tr>
<tr>
<td>Sibbitt et al., 2011</td>
<td>92</td>
<td>Knee</td>
<td>RCT</td>
<td>US</td>
<td>US-guided vs blind triamcinolone in terms of pain relief, pain related to the injection, reinjection rate and cost Significant decrease in pain only in patients treated with US-guided injection; US-guided procedure was related to lower pain and reinjection rate, but higher costs</td>
</tr>
<tr>
<td>Karalezli et al., 2007</td>
<td>16</td>
<td>Hand</td>
<td>Cohort</td>
<td>CR</td>
<td>Fluoroscopy-guided vs blind injections of HA in the trapezio-metacarpal joint in terms of pain related to the injection VAS pain related to the procedure: fluoroscopic guide: 4.1 (range 3–6), anatomic guide 5.6 (range 3–7); p&lt;0.005 No significant difference in terms of safety</td>
</tr>
</tbody>
</table>

CR, conventional radiography; HA, hyaluronic acid; N, number of participants; OA, osteoarthritis; RCT, randomised controlled trial; US, ultrasonography; VAS, visual analogue scale.

Table 6 Future research agenda

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 There is a need for methodologically robust studies to explore the added value of imaging (any modality) to clinical diagnosis or differential diagnosis.</td>
</tr>
<tr>
<td>2 What is the cost-effectiveness of imaging in osteoarthritis clinical practice?</td>
</tr>
<tr>
<td>3 Is imaging able to help in identification of subgroups/phenotypes that may have different trajectories and enable targeted treatment based on these subgroups?</td>
</tr>
<tr>
<td>4 There is a need to understand if using imaging to measure response to therapy is of clinical benefit. This may require evaluation of novel imaging technologies that are able to sensitively detect change in relevant joint structures.</td>
</tr>
<tr>
<td>5 Quality studies are required to explore imaging (any modality) features that predict response to specific therapies.</td>
</tr>
<tr>
<td>6 There is a need for more research concerning the benefits of imaging in less commonly studied osteoarthritis sites such as the foot and shoulder.</td>
</tr>
<tr>
<td>7 Specifically for hip osteoarthritis, what is the added value of weightbearing vs non-weightbearing X-rays?</td>
</tr>
<tr>
<td>8 What are the benefits of imaging guidance in improving the efficacy of treatments?</td>
</tr>
</tbody>
</table>

Author affiliations
1 Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy
2 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK
3 Academic Rheumatology, Clinical Sciences Building, University of Nottingham, Nottingham City Hospital, Nottingham, UK
4 Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
5 Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
6 APHP, Hôpital Ambroise Paré, Service de Rhumatologie, Boulogne-Billancourt, France
The authors would like to thank EULAR for the GS and PGC produced drafts of the manuscript with advice from AI and WZ. All GS and PGC contributed equally. GS performed the literature review.

Contributors
The authors thank Mrs Jaqueline Mäder for participating to work. PGC is supported in part by the National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit.

Disclaimer
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Competing interests
None.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES


Haugen IK, Slatkowsky-Christensen B, Bøyesen P, et al. Longitudinal and symptomatic changes in volume in the majority of patients with osteoarthritis; associations with clinical symptoms or physical examination and symptoms or physical examination. *Eur Radiol* 2007;17:3073–8.


